Nucleoside/nucleotide analogue (NA) treatment causes selection pressure for HBV strains carrying mutations conferring NA resistance. Drug-resistance mutations occur in the reverse transcriptase (RT) region of the HBV polymerase gene and spontaneously arise during viral replication. These mutations can also alter the hepatitis B surface (HBs) protein and in some cases reduce binding to HBs antibodies. The spread of NA-resistant HBV may impact the efficacy of antiviral treatment and hepatitis B immunization programmes. In this study, we used direct sequencing to assess the occurrence of HBV carrying known mutations that confer NA resistance in the largest cohort of treatment-naive patients with chronic hepatitis B (CHB) to date.
Methods
HBV DNA samples isolated from 702 patients were sequenced and the RT region subjected to mutational analysis.
Results
There was high genetic variability among the HBV samples analysed: A1 (63.7%), D3 (14.5%), A2 (3.3%), A3 (0.1%), B1 (0.1%), B2 (0.1%), C2 (0.9%), D1 (0.9%), D2 (4.6%), D4 (5.1%), D unclassified sub-genotype (0.7%), E (0.6%), F2a (4.6%), F4 (0.4%) and G (0.4%). HBV strains harbouring mutations conferring NA resistance alone or combined with compensatory mutations were identified in 1.6% (11/702) of the patients.
Conclusions
HBV strains harbouring resistance mutations can comprise the major population of HBV quasispecies in treatment-naive patients. In Brazil, there is a very low frequency of untreated patients who are infected with these strains. These findings suggest that the spread and natural selection of drug-resistant HBV is an uncommon event and/or most of these strains remain unstable in the absence of NA selective pressure.
References
1.
TeH.S., JensenD.M.Epidemiology of hepatitis B and C viruses: a global overview.Clin Liver Dis2010; 14: 1–21.
PereiraL.M., MartelliC.M., Merchan-HamannE.Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil.Am J Trop Med Hyg2009; 81: 240–247.
4.
Ministério da Saúde, Departamento de DST, Aids e Hepatites Virais Secretaria de Vigilância em Saúde. [Viral hepatitis in Brazil: state and actions]. Agenda 2011. Portuguese.
5.
Ministério da Saúde, Departamento de DST, Aids e Hepatites Virais. [Clinical protocol and therapeutic guidelines for the treatment of chronic viral hepatitis and coinfections]. 2011. Portuguese.
6.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t) ide analogues.Gastroenterology2009; 137: 1593–1608.
7.
KamiliS., SozziV., ThompsonG.Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.Hepatology2009; 49: 1483–1491.
8.
Alvarez EstévezM., Chueca-PorcunaN., Guillot-SuayV., Pena-MonjeA., Garcia-GarciaF., Garcia-GarciaF.[Low prevalence of hepatitis B virus primary drug resistance in Southern Spain].Enferm Infecc Microbiol Clin2013; 31: 520–522. Spanish.
9.
HanY., HuangL.H., LiuC.M.Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients.J Gastroenterol Hepatol2009; 24: 1417–1423.
10.
IsmailA.M., SamuelP., EapenC.E., KannangaiR., AbrahamP.Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naive hepatitis B virus-infected individuals from the Indian subcontinent.Intervirology2012; 55: 36–44.
11.
JardiR., Rodriguez-FriasF., SchaperM.Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.J Viral Hepat2007; 14: 835–840.
12.
LiX.G., LiuB.M., XuJ., LiuX.E., DingH., LiT.Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China.J Med Virol2012; 84: 207–216.
13.
LiuB.M., LiT., XuJ.Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients.Antiviral Res2010; 85: 512–519.
14.
MantovaniN., CiceroM., SantanaL.C.Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and Sao Paulo, Brazil.Virol J2013; 10: 320.
15.
MohebbiS.R., Amini-Bavil-OlyaeeS., ZaliN.Characterization of hepatitis B virus genome variability in Iranian patients with chronic infection, a nationwide study.J Med Virol2012; 84: 414–423.
16.
MorandoF., RosiS., FasolatoS.Severe acute hepatitis B in a treatment-naive patient with antiviral drug resistant mutations in the polymerase gene.J Med Virol2013; 85: 210–213.
17.
NguyenM.H., GarciaR.T., TrinhH.N.Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naive patients with chronic hepatitis B.Aliment Pharmacol Ther2009; 30: 1150–1158.
18.
PollicinoT., IsgroG., Di StefanoR.Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.Antivir Ther2009; 14: 649–654.
19.
SalpiniR., SvicherV., CentoV.Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs.Antiviral Res2011; 92: 382–385.
20.
SayanM., AkhanS.C.Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.Int J Infect Dis2011; 15: e722–e726.
21.
SayanM., AkhanS.C., MericM.Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B.J Viral Hepat2010; 17: 23–27.
22.
SayanM., SenturkO., AkhanS.C., HulaguS., CekmenM.B.Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B.Int J Infect Dis2010; 14Suppl 3: e136–e141.
23.
SinglaB., ChakrabortiA., SharmaB.K.Hepatitis B virus reverse transcriptase mutations in treatment naive chronic hepatitis B patients.J Med Virol2013; 85: 1155–1162.
24.
TreviñoA., SorianoV., MadejonA.Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.AIDS Res Hum Retroviruses2009; 25: 1273–1276.
25.
XuZ., LiuY., XuT.Acute hepatitis B infection associated with drug-resistant hepatitis B virus.J Clin Virol2010; 48: 270–274.
26.
ZhengJ., ZengZ., ZhangD., YuY., WangF., PanC.Q.Prevalence and significance of hepatitis B reverse transcriptase mutants in different disease stages of untreated patients.Liver Int2012; 32: 1535–1542.
27.
MelloF.C., FernandesC.A., Gomes SdeA.Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes.Mem Inst Oswaldo Cruz2012; 107: 317–325.
28.
SitnikR., PaesA., MangueiraC.P., PinhoJ.R.R.A real-time quantitative assay for hepatitis B DNA virus (HBV) developed to detect all HBV genotypes.Rev Inst Med Trop Sao Paulo2010; 52: 119–124.
29.
LokA.S., ZoulimF., LocarniniS.Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.Hepatology2007; 46: 254–265.
30.
KaratayliE., KaratayliS.C., CinarK.Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.J Clin Virol2012; 53: 130–134.
31.
MelloF.C., SoutoF.J., NabucoL.C.Hepatitis B virus genotypes circulating in Brazil: molecular characterization of genotype F isolates.BMC Microbiol2007; 7: 103.
32.
SitnikR., PinhoJ.R., BertoliniD.A., BernardiniA.P., Da SilvaL.C., CarrilhoF.J.Hepatitis B virus genotypes and precore and core mutants in Brazilian patients.J Clin Microbiol2004; 42: 2455–2460.
33.
TenneyD.J., LevineS.M., RoseR.E.Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine.Antimicrob Agents Chemother2004; 48: 3498–3507.
34.
SelabeS.G., LukhwareniA., SongE., LeeuwY.G., BurnettR.J., MphahleleM.J.Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.J Med Virol2007; 79: 1650–1654.
35.
ThioC.L., SmeatonL., SaulynasM.Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort.AIDS2013; 27: 191–201.
36.
MelloF.C., LagoB.V., Lewis-XimenezL.L., FernandesC.A., GomesS.A.Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients.BMC Microbiol2012; 12: 96.
37.
DelaneyW.E., YangH., WestlandC.E.The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.J Virol2003; 77: 11833–11841.
38.
Margeridon-ThermetS., SvarovskaiaE.S., BabrzadehF.Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of lamivudine treatment.Antimicrob Agents Chemother2013; 57: 343–349.
39.
YehC.T.Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.Antivir Ther2010; 15: 471–475.
40.
TorresiJ., Earnest-SilveiraL., DeliyannisG.Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.Virology2002; 293: 305–313.
41.
BartholomeuszA., LocarniniS.A.Antiviral drug resistance: clinical consequences and molecular aspects.Semin Liver Dis2006; 26: 162–170.
42.
LeeY.S., ChungY.H., KimJ.A.rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.J Gastroenterol Hepatol2012; 27: 300–305.
43.
LiuL.J., WangJ.H., DuS.C., TianJ.H., YangR.F., WeiL.rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.J Viral Hepat2010; 17Suppl 1: 66–72.
44.
QinB., PeiR.J., HeT.T.Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir.Chin Sci Bull2013; 58: 1760–1766.
45.
SchildgenO., OlotuC., FunkA.Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.J Clin Microbiol2010; 48: 631–634.
46.
SheldonJ., RodesB., ZoulimF., BartholomeuszA., SorianoV.Mutations affecting the replication capacity of the hepatitis B virus.J Viral Hepat2006; 13: 427–434.
47.
Amini-Bavil-OlyaeeS., HerbersU., MohebbiS.R.Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.J Hepatol2009; 51: 647–654.
48.
Borroto-EsodaK., MillerM.D., ArterburnS.Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials.J Hepatol2007; 47: 492–498.
49.
De MaddalenaC., GiambelliC., TanziE.High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus.Virology2007; 365: 113–124.
50.
BottecchiaM., MadejonA., SheldonJ., Garcia-SamaniegoJ., BarreiroP., SorianoV.Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir.J Antimicrob Chemother2008; 62: 626–627.
51.
CurtisM., ZhuY., Borroto-EsodaK.Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir.J Infect Dis2007; 196: 1483–1486.
52.
KhudyakovY.Coevolution and HBV drug resistance.Antivir Ther2010; 15: 505–515.
